New LEGION™ Narrow Femoral Components with OXINIUM™ offer improved patient specific fit and wear performance

  New LEGION™ Narrow Femoral Components with OXINIUM™ offer improved patient
                      specific fit and wear performance

PR Newswire

LONDON, Dec. 19, 2012

LONDON, Dec. 19, 2012 /PRNewswire/ --Smith & Nephew (LSE: SN, NYSE: SNN), the
global medical technology business, today announces an extension to its highly
successful LEGION™ Total Knee System - LEGION™ Narrow Femoral Components with
OXINIUM™ Oxidized Zirconium. The only narrow components that offer Smith &
Nephew's proprietary VERILAST™ Technology, these new implants offer surgeons
and their patients the potential for implants with better fit and wear

These new LEGION components are thinner in the medial/lateral dimension
(side-to-side) to give surgeons the ability to more closely fit a patient's
natural anatomy. For patients with smaller femurs, using a femoral component
that is too wide can result in overhang of the femoral component. Studies have
shown that improving implant fit can reduce pain and increase satisfaction
among total knee replacement patients.^i

In addition to fit, the new femoral components address implant wear
performance with the use of VERILAST Technology. The combination of two wear
reducing materials – the proprietary OXINIUM alloy and a highly cross-linked
plastic liner, VERILAST Technology has the potential to improve the wear
performance of an implant. In fact, even on traditional plastic liners,
OXINIUM implants are 4,900 times more abrasion resistant than cobalt chrome
and have been shown in lab testing to reduce artificial joint wear by
85-percent compared to cobalt chromium femoral components.^ii

"These new components further demonstrate the LEGION Total Knee System's
commitment to patient specific fit," says Dr. Steven Haas, Chief of Knee
Service at The Hospital for Special Surgery in New York City. "When you add
the LEGION Narrow options to the system's existing asymmetric tibias,
gender-based sizing and advanced bearing materials, the ability for me to
optimize fit for each of my patients is really exciting."

"Two of the biggest concerns with any total knee replacement are wear
performance and fit," explains Scott Elliott, SVP & General Manager,
Reconstructive Strategic Business Unit for Smith & Nephew's Advanced Surgical
Devices Division. "With the LEGION Total Knee System, we offer an
unprecedented solution to both: VERILAST Technology for wear performance and
new size options to address patient fit."

First introduced in 1997, the LEGION Total Knee System is a comprehensive
system that allows surgeons to address a diverse range of surgical challenges
with one system of instrumentation and components. The system includes both
cruciate retaining and posterior stabilized primary knees, as well as revision
knees and has more than 15 years of clinical history and continues to achieve
outstanding clinical outcomes.^iii

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping
improve people's lives. With leadership positions in Orthopaedic
Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith &
Nephew has almost 11,000 employees and a presence in more than 90 countries.
Annual sales in 2011 were nearly $4.3 billion. Smith & Nephew is a member of

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target", "consider" and
similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to
differ materially from what is expressed or implied by the statements. For
Smith & Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care providers, payors
and customers; price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals, reimbursement
decisions or other government actions; product defects or recalls; litigation
relating to patent or other claims; legal compliance risks and related
investigative, remedial or enforcement actions; strategic actions, including
acquisitions and dispositions, our success in integrating acquired businesses,
and disruption that may result from changes we make in our business plans or
organisation to adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic, business
or competitive nature. Please refer to the documents that Smith & Nephew has
filed with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith & Nephew's most
recent annual report on Form 20-F, for a discussion of certain of these

Any forward-looking statement is based on information available to Smith &
Nephew as of the date of the statement. All written or oral forward-looking
statements attributable to Smith & Nephew are qualified by this caution. Smith
& Nephew does not undertake any obligation to update or revise any
forward-looking statement to reflect any change in circumstances or in Smith &
Nephew's expectations.

Trademark of Smith & Nephew. Registered US Patent and Trademark Office.

^i Overhang of the Femoral Component in Total Knee Arthroplasty: Risk Factors
and Clinical Consequences; JBJS 2010 ; Ormonde M. Mahoney, MD

^ii G. Hunter and M. Long, "Abrasive wear of oxidized Zr-2.5Nb, CoCrMo, and
Ti-6Al-4V against bone cement", 6th World Biomaterials Cong. Trans., Society
For Biomaterials, Minneapolis, MN, 2000, p. 835.

^iii Based on GENESIS II clinical data; Knee. 2012 Jan;19(1):8-13. Epub 2011
Apr 14., The Genesis II in primary total knee replacement: a systematic
literature review of clinical outcomes., Bhandari M, Pascale W, Sprague S,
Pascale V.

SOURCE Smith & Nephew

Contact: Brad Merrick, Media, Smith & Nephew, +1-901-399-1089,; or, Phil Cowdy, Media Investor/Analyst, Smith &
Nephew, 44 (0)20 7401 7646,
Press spacebar to pause and continue. Press esc to stop.